A phase I and pharmacokinetic (PK) study of high dose selenomethionine (SLM) in combination with irinotecan (IRI) in patients with advanced solid tumors

MLA

Shousong Cao, et al. “A Phase I and Pharmacokinetic (PK) Study of High Dose Selenomethionine (SLM) in Combination with Irinotecan (IRI) in Patients with Advanced Solid Tumors.” Journal of Clinical Oncology, vol. 23, June 2005, p. 2080. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........d0a4d178bbd37e70b88a3089626925e2&authtype=sso&custid=ns315887.

APA

Shousong Cao, Patrick J. Creaven, F. Durrani, Lakshmi Pendyala, Patrick F. Smith, David Lawrence, R.G. Azrak, N. C. Diane, Youcef M. Rustum, Marwan Fakih, & V. Badmaev. (2005). A phase I and pharmacokinetic (PK) study of high dose selenomethionine (SLM) in combination with irinotecan (IRI) in patients with advanced solid tumors. Journal of Clinical Oncology, 23, 2080.

Chicago

Shousong Cao, Patrick J. Creaven, F. Durrani, Lakshmi Pendyala, Patrick F. Smith, David Lawrence, R.G. Azrak, et al. 2005. “A Phase I and Pharmacokinetic (PK) Study of High Dose Selenomethionine (SLM) in Combination with Irinotecan (IRI) in Patients with Advanced Solid Tumors.” Journal of Clinical Oncology 23 (June): 2080. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........d0a4d178bbd37e70b88a3089626925e2&authtype=sso&custid=ns315887.